DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Additive hypoglycaemic effect of nateglinide and exogenous glucagon-like peptide-1 in type 2 diabetes.

Author(s): Bell PM, Cuthbertson J, Patterson S, O'Harte FP

Affiliation(s): Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, UK. patrick.bell@belfasttrust.hscni.net

Publication date & source: 2011-03, Diabetes Res Clin Pract., 91(3):e68-70. Epub 2010 Dec 30.

Publication type: Clinical Trial; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

We examined the postprandial glucose regulators nateglinide and GLP-1, separately and in combination, in people with type 2 diabetes. Nateglinide inhibited DPP-4 activity, reduced GLP-1 degradation and enhanced its insulinotropic and blood glucose lowering effect. Combining nateglinide and GLP-1 derivatives may effectively control postprandial glycaemia. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017